Novel targets in bone and cartilage

Best Practice and Research: Clinical Rheumatology

Volumn 24, Issue 4, 2010, Pages 489-496

  Beyer, Christian ^a   Schett, Georg ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

bone; cartilage: FGF 18; hedgehog; RANKL; sclerostin; targets; Wnt

Indexed keywords

BALICATIB; CATHEPSIN K; DENOSUMAB; DICKKOPF 1 PROTEIN; FIBROBLAST GROWTH FACTOR 18; ODANACATIB; OSTEOCLAST DIFFERENTIATION FACTOR; SCLEROSTIN; SONIC HEDGEHOG PROTEIN; WNT PROTEIN; ANTIRHEUMATIC AGENT; BONE MORPHOGENETIC PROTEIN; CTSK PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; SOST PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; BIOSYNTHESIS; BONE; BONE DEFECT; BONE EROSION; BONE REMODELING; CARTILAGE; CARTILAGE DEGENERATION; CATABOLISM; HUMAN; OSSIFICATION; OSTEOARTHRITIS; OSTEOCLAST; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCLEROSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; ARTICULAR CARTILAGE; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; DRUG EFFECT; GENETIC MARKER; METABOLISM; PHYSIOLOGY; REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS; BONE AND BONES; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; CARTILAGE, ARTICULAR; CATHEPSIN K; CLINICAL TRIALS AS TOPIC; FIBROBLAST GROWTH FACTORS; GENETIC MARKERS; HEDGEHOG PROTEINS; HUMANS; RANK LIGAND; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 77956163932     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2010.03.001     Document Type: Review

References (76)

1. G. Schett Joint remodelling in inflammatory disease Annals of the Rheumatic Diseases 66 Suppl. 3 2007 iii42 iii44
2. K. Redlich, S. Hayer, and R. Ricci Osteoclasts are essential for TNF-alpha-mediated joint destruction The Journal of Clinical Investigation 110 10 2002 1419 1427
3. W.J. Boyle, W.S. Simonet, and D.L. Lacey Osteoclast differentiation and activation Nature 423 6937 2003 337 342
4. M.B. Goldring, and K.B. Marcu Cartilage homeostasis in health and rheumatic diseases Arthritis Research & Therapy 11 3 2009 224
5. J. Lam, S. Takeshita, and J.E. Barker TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand The Journal of Clinical Investigation 106 12 2000 1481 1488
6. E. Lubberts, L. van den Bersselaar, and B. Oppers-Walgreen IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance Journal of Immunology 170 5 2003 2655 2662
7. K. Sato, A. Suematsu, and K. Okamoto Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction The Journal of Experimental Medicine 203 12 2006 2673 2682
8. S. Wei, H. Kitaura, and P. Zhou IL-1 mediates TNF-induced osteoclastogenesis The Journal of Clinical Investigation 115 2 2005 282 290
9. I.B. McInnes, and G. Schett Cytokines in the pathogenesis of rheumatoid arthritis Nature Reviews. Immunology 7 6 2007 429 442
10. H. Takayanagi Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems Nature Reviews. Immunology 7 4 2007 292 304
11. E.M. Gravallese, C. Manning, and A. Tsay Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor Arthritis and Rheumatism 43 2 2000 250 258
12. O. Vasiljeva, T. Reinheckel, and C. Peters Emerging roles of cysteine cathepsins in disease and their potential as drug targets Current Pharmaceutical Design 13 4 2007 387 403
13. J.S. Smolen, P.E. Lipsky, Biological therapies in rheumatology 2002 Taylor & Francis Ltd. London
14. Y.Y. Kong, H. Yoshida, and I. Sarosi OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature 397 6717 1999 315 323
15. D.L. Lacey, E. Timms, and H.L. Tan Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 2 1998 165 176
16. W.S. Simonet, D.L. Lacey, and C.R. Dunstan Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 2 1997 309 319
17. E. Romas, N.A. Sims, and D.K. Hards Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis The American Journal of Pathology 161 4 2002 1419 1427
18. K. Redlich, B. Gortz, and S. Hayer Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis The American Journal of Pathology 164 2 2004 543 555
19. G. Schett, S. Middleton, and B. Bolon Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models Arthritis and Rheumatism 52 5 2005 1604 1611
20. Y.Y. Kong, U. Feige, and I. Sarosi Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand Nature 402 6759 1999 304 309
21. B. Bolon, G. Campagnuolo, and U. Feige Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis Cellular and Molecular Life Sciences 59 9 2002 1569 1576
22. G. Schett, M. Stolina, and D. Dwyer Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis Arthritis and Rheumatism 60 9 2009 2644 2654
23. L.M. Flick, J.M. Weaver, and M. Ulrich-Vinther Effects of receptor activator of NFkappaB (RANK) signalling blockade on fracture healing Journal of Orthopaedic Research 21 4 2003 676 684
24. M. Stolina, G. Schett, and D. Dwyer RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies Arthritis Research & Therapy 11 6 2009 R187
25. G. Schett, S. Hayer, and J. Zwerina Mechanisms of disease: the link between RANKL and arthritic bone disease Nature Clinical Practice. Rheumatology 1 1 2005 47 54
26. P.J. Bekker, D. Holloway, and A. Nakanishi The effect of a single dose of osteoprotegerin in postmenopausal women Journal of Bone and Mineral Research 16 2 2001 348 360
27. J.J. Body, P. Greipp, and R.E. Coleman A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases Cancer 97 3 Suppl. 2003 887 892
28. P.J. Bekker, D.L. Holloway, and A.S. Rasmussen A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004 Journal of Bone and Mineral Research 20 12 2005 2275 2282
29. M.R. McClung, E.M. Lewiecki, and S.B. Cohen Denosumab in postmenopausal women with low bone mineral density The New England Journal of Medicine 354 8 2006 821 831
30. F. Eggelmeijer, S.E. Papapoulos, and H.C. van Paassen Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial Arthritis and Rheumatism 39 3 1996 396 402
31. A. Maccagno, E. Di Giorgio, and E.J. Roldan Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis Scandinavian Journal of Rheumatology 23 4 1994 211 214
32. S.H. Ralston, L. Hacking, and L. Willocks Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis Annals of the Rheumatic Diseases 48 5 1989 396 399
33. S.B. Cohen, R.K. Dore, and N.E. Lane Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial Arthritis and Rheumatism 58 5 2008 1299 1309
34. X. Li, P. Liu, and W. Liu Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation Nature Genetics 37 9 2005 945 952
35. X. Li, Y. Zhang, and H. Kang Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signalling The Journal of Biological Chemistry 280 20 2005 19883 19887
36. D. Diarra, M. Stolina, and K. Polzer Dickkopf-1 is a master regulator of joint remodeling Nature Medicine 13 2 2007 156 163
37. Ettenberg S, Cong F, Shulok J, et al. BHQ880, a novel anti-DKK1 neutralizing antibody, inhibits tumor-induced osteolytic bone disease. American Association for Cancer Research Annual Meeting, April 12-16, 2008, San Diego, California.
38. H.Y. Choi, M. Dieckmann, J. Herz, and A. Niemeier Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo PLoS One 4 11 2009 e7930
39. D.G. Winkler, M.S. Sutherland, and E. Ojala Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins The Journal of Biological Chemistry 280 4 2005 2498 2502
40. M. Semenov, K. Tamai, and X. He SOST is a ligand for LRP5/LRP6 and a Wnt signalling inhibitor The Journal of Biological Chemistry 280 29 2005 26770 26775
41. G.G. Loots, M. Kneissel, and H. Keller Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease Genome Research 15 7 2005 928 935
42. D.G. Winkler, M.K. Sutherland, and J.C. Geoghegan Osteocyte control of bone formation via sclerostin, a novel BMP antagonist The EMBO Journal 22 23 2003 6267 6276
43. X. Li, M.S. Ominsky, and Q.T. Niu Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength Journal of Bone and Mineral Research 23 6 2008 860 869
44. M.E. Brunkow, J.C. Gardner, and J. Van Ness Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein American Journal of Human Genetics 68 3 2001 577 589
45. H. Appel, G. Ruiz-Heiland, and J. Listing Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis Arthritis and Rheumatism 60 11 2009 3257 3262
46. K.E. Poole, R.L. van Bezooijen, and N. Loveridge Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation The FASEB Journal 19 13 2005 1842 1844
47. Y. Dong, H. Drissi, and M. Chen Wnt-mediated regulation of chondrocyte maturation: modulation by TGF-beta Journal of Cellular Biochemistry 95 5 2005 1057 1068
48. M. Chen, M. Zhu, and H. Awad Inhibition of beta-catenin signalling causes defects in postnatal cartilage development Journal of Cell Science 121 Pt 9 2008 1455 1465
49. T. Yuasa, T. Otani, and T. Koike Wnt/beta-catenin signalling stimulates matrix catabolic genes and activity in articular chondrocytes: its possible role in joint degeneration Laboratory Investigation 88 3 2008 264 274
50. R.J. Lories, J. Peeters, and A. Bakker Articular cartilage and biomechanical properties of the long bones in Frzb-knockout mice Arthritis and Rheumatism 56 12 2007 4095 4103
51. Y. Chen, H.C. Whetstone, and A.C. Lin Beta-catenin signalling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing PLoS Med 4 7 2007 e249
52. F. Dell'accio, C. De Bari, and N.M. Eltawil Identification of the molecular response of articular cartilage to injury, by microarray screening: Wnt-16 expression and signalling after injury and in osteoarthritis Arthritis and Rheumatism 58 5 2008 1410 1421
53. S. Kakar, T.A. Einhorn, and S. Vora Enhanced chondrogenesis and Wnt signalling in PTH-treated fractures Journal of Bone and Mineral Research 22 12 2007 1903 1912
54. S.A. Stoch, and J.A. Wagner Cathepsin K inhibitors: a novel target for osteoporosis therapy Clinical Pharmacology and Therapeutics 83 1 2008 172 176
55. U. Schurigt, K.M. Hummel, and P.K. Petrow Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice Arthritis and Rheumatism 58 2 2008 422 434
56. M. Asagiri, T. Hirai, and T. Kunigami Cathepsin K-dependent toll-like receptor 9 signalling revealed in experimental arthritis Science 319 5863 2008 624 627
57. C. Deal Future therapeutic targets in osteoporosis Current Opinion in Rheumatology 21 4 2009 380 385
58. S. Adami, J. Supronik, and T. Hala Effect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis Journal of Bone and Mineral Research 21 Suppl. 1 2006 Abstract 1085
59. P. Papanastasiou, C. Ortmann, and M. Olson Effect of three month treatment with the cathepsin-K inhibitor, balicatib, on biochemical markers of bone turnover in postmenopausal women: evidence for uncoupling of bone resorption and bone formation Journal of Bone and Mineral Research 21 Suppl. 1 2006 Abstract 1223
60. S.A. Stoch, S. Zajic, and J. Stone Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies Clinical Pharmacology and Therapeutics 86 2 2009 175 182
61. F. Deschaseaux, L. Sensebe, and D. Heymann Mechanisms of bone repair and regeneration Trends in Molecular Medicine 15 9 2009 417 429
62. S. Ohba, H. Kawaguchi, and F. Kugimiya Patched1 haploinsufficiency increases adult bone mass and modulates Gli3 repressor activity Developmental Cell 14 5 2008 689 699
63. K.K. Mak, Y. Bi, and C. Wan Hedgehog signalling in mature osteoblasts regulates bone formation and resorption by controlling PTHrP and RANKL expression Developmental Cell 14 5 2008 674 688
64. A.C. Lin, B.L. Seeto, and J.M. Bartoszko Modulating hedgehog signalling can attenuate the severity of osteoarthritis Nature Medicine 15 12 2009 1421 1425
65. L. Lum, and P.A. Beachy The Hedgehog response network: sensors, switches, and routers Science 304 5678 2004 1755 1759
66. T.C. Ng, K.W. Chiu, A.B. Rabie, and U. Hagg Repeated mechanical loading enhances the expression of Indian hedgehog in condylar cartilage Frontiers in Bioscience 11 2006 943 948
67. T. Aigner, S. Soder, and P.M. Gebhard Mechanisms of disease: role of chondrocytes in the pathogenesis of osteoarthritis-structure, chaos and senescence Nature Clinical Practice. Rheumatology 3 7 2007 391 399
68. D.M. Ornitz FGFs, heparan sulfate and FGFRs: complex interactions essential for development Bioessays 22 2 2000 108 112
69. Z. Liu, J. Xu, J.S. Colvin, and D.M. Ornitz Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18 Genes & Development 16 7 2002 859 869
70. V.P. Eswarakumar, E. Monsonego-Ornan, and M. Pines The IIIc alternative of Fgfr2 is a positive regulator of bone formation Development 129 16 2002 3783 3793
71. D.M. Ornitz, and P.J. Marie FGF signalling pathways in endochondral and intramembranous bone development and human genetic disease Genes & Development 16 12 2002 1446 1465
72. J.L. Ellsworth, J. Berry, and T. Bukowski Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors Osteoarthritis Cartilage 10 4 2002 308 320
73. D. Davidson, A. Blanc, and D. Filion Fibroblast growth factor (FGF) 18 signals through FGF receptor 3 to promote chondrogenesis The Journal of Biological Chemistry 280 21 2005 20509 20515
74. N. Ohbayashi, M. Shibayama, and Y. Kurotaki FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis Genes & Development 16 7 2002 870 879
75. H. Yamaoka, S. Nishizawa, and Y. Asawa Involvement of fibroblast growth factor 18 in dedifferentiation of cultured human chondrocytes Cell Proliferation 43 1 2010 67 76
76. E.E. Moore, A.M. Bendele, and D.L. Thompson Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis Osteoarthritis Cartilage 13 7 2005 623 631